ブログ

Read a recap of the 16th World ADC San Diego 2025 conference that was held in San Diego, California, from November 3 to November 6, 2025!

Discover how immune, naïve and synthetic VHH libraries are built, biopanned and optimized for therapeutic, diagnostic, imaging and research use globally now.

In the traditional antibody discovery paradigm, developability is often treated as a downstream quality control issue, as something to verify once a candidate has been selected for advancement. However, a shift in mindset is emerging within the biopharmaceutical industry: developability must be a design principle from the outset.

Developability is the likelihood that an antibody candidate will proceed through the chemistry, manufacturing, and control (CMC) process efficiently, at acceptable cost, and on schedule. There is a critical distinction between early-stage (discovery) and late-stage (CMC) developability assessments.

BioJapan 2025 was held in Yokohama, Japan, from October 8 to October 10, 2025. The exhibition highlighted advances across AI-accelerated R&D, CRO integration, and cross-border innovation partnerships.Popular topics included:Antibody & Biologics DiscoveryAI and Data in Clinical Re

Each year, the Nobel Prizes recognize breakthroughs that reshape our understanding of the natural world. The 2025 awards in Chemistry and Physiology or Medicine highlight discoveries that bridge fundamental science and real-world impact, from molecular materials that can breathe gases to immune mechanisms that prevent the body from attacking itself.

BIOPLUS-INTERPHEX KOREA was held in Seoul, Korea, from October 15 to October 17, 2025. The exhibition highlighted advances across the biopharmaceutical value chain and showcased the latest trends.

Learn how synthetic phage-displayed VHH libraries are designed and built. Explore workflows, advantages, applications, and challenges in antibody discovery.

According to published analyses, approximately 90% of drug candidates fail during clinical development, and this figure may exceed 99% when preclinical stages are included. Learn about antibody developability.

Antibody developability refers to the set of biochemical, biophysical, and structural attributes that influence the manufacturability, stability, and clinical viability of an antibody candidate. Simply, developability assesses the likelihood that a candidate will become a safe and efficacious drug. While biological activity and binding affinity remain central to therapeutic antibody selection, developability has emerged as a critical parameter in determining whether a candidate can advance successfully through preclinical development and into the clinic.

The Festival of Biologics 2025 was held in Basel, Switzerland, from September 30 to October 2, 2025. The event highlighted advances across discovery, development, clinical trials, manufacturing, market access, and fill & finish. As Europe’s largest biologics event,3000+ attendees and 350

The 23rd Annual Discovery on Target conference was held in Boston, MA, USA, from September 22-25, 2025. The event highlighted advances across protein degradation, induced proximity, synthetic biology, AI-enabled design, immune modulation, and 3D organoid modeling, alongside GLP-1 biology, MASH and obesity, ADCs, and multispecifics.